In Brief: RGene Therapeutics/Groupe Fournier
Executive Summary
RGene Therapeutics/Groupe Fournier: Announce collaborative agreement to develop E1A tumor suppressor gene therapy for the treatment of cancer. The product is currently in a Phase I trial in patients with advanced ovarian cancer and metastatic breast cancer that overexpress the HER-2/neu oncogene. Dijon, France-based Fournier could pay up to $25 mil. in an up-front licensing fee, milestone payments and development costs. RGene's merger with Targeted Genetics of Seattle is expected to close in June...